Case Summary (UDK No. 16838)
Reliefs Sought by Petitioner
Petitioner sought a writ of mandamus compelling respondents to (a) observe Food and Drug Administration (FDA) rules on acquisition, procurement, and use of drugs; (b) require COVID-19 vaccines, including the Sinovac vaccine, to undergo required clinical trials in the Philippines before emergency or regular use; and (c) direct the DOH-FDA to issue a Cease-and-Desist Order for the purchase and use of the Sinovac vaccine.
Core Factual Concerns Presented
At the heart of the petition is petitioner’s concern about the national government’s plan to procure and distribute Sinovac vaccines to contain SARS-CoV-2 infections. The petition emphasized reported doubts about Sinovac’s efficacy and the absence of a “concrete study” on how the vaccine performs against COVID-19, thereby asserting that additional local trials and adherence to procurement law should be required before use.
Procedural and Jurisdictional Threshold: Presidential Immunity
The Court held that an incumbent President cannot be sued during his tenure and therefore must be dropped as a respondent. The decision relied on prior jurisprudence (e.g., De Lima v. President Duterte, Rubrico v. Macapagal‑Arroyo) recognizing presidential immunity under the constitutional framework. The immunity is described as absolute during tenure, not dependent on the nature of the suit or whether the acts are official or private; accountability is preserved through impeachment, not ordinary suits. Consequently, President Duterte was not a proper party to the mandamus petition.
Governing Constitutional Framework Applied
Because the decision date falls in 2021, the Court applied the 1987 Constitution as the constitutional basis for its rulings, particularly the doctrine vesting executive power in the President and the rationale for presidential immunity to prevent distraction from official duties.
Legal Standard for a Writ of Mandamus
The Court applied Section 3, Rule 65 of the Revised Rules of Court. Mandamus may issue when: (1) a tribunal, corporation, board, officer, or person unlawfully neglects to perform an act specifically enjoined as a duty of office, trust, or station; or (2) one unlawfully excludes another from the use and enjoyment of a right or office. For the first situation (invoked here), petitioner must: (a) identify a specific legal provision imposing the duty; (b) show the duty is ministerial (i.e., the act is prescribed, requires no exercise of judgment, and must be performed upon the occurrence of specified facts); and (c) demonstrate no other plain, speedy, and adequate remedy exists.
Ministerial versus Discretionary Duty Analysis
The Court reiterated precedents explaining that mandamus compels ministerial, not discretionary, duties. A ministerial duty is performed in a prescribed manner given a prescribed state of facts and does not allow the officer to exercise discretion. If the law confers the official a right to decide how or when the duty shall be performed, the duty is discretionary and not subject to mandamus.
Application of the Mandamus Standard to the Petition
Applying the standard, the Court found petitioner failed to identify any statute or regulation imposing a ministerial duty on respondents to conduct clinical trials in the Philippines prior to procurement or to adhere to standard public bidding procedures in the procurement of COVID‑19 vaccines. At the relevant time, there was no law mandating mandatory local clinical trials for COVID‑19 vaccines; in fact, Section 12 of R.A. No. 11494 (Bayanihan to Recover as One Act) temporarily suspended the requirement for Phase IV trials for COVID‑19 vaccines for three months and allowed discretion consistent with WHO and other internationally recognized guidelines.
Statutory Delegation and Executive Discretion under R.A. No. 11494
R.A. No. 11494 authorized the President to exercise powers necessary and proper to undertake COVID‑19 response and recovery interventions, including adoption of WHO/CDC guidelines and delivery of immunization programs. Section 12 expressly waived the Phase IV trial requirement for COVID‑19 vaccines (for a defined period) provided the vaccines are recommended and approved by WHO or other internationally recognized health agencies, and empowered the FDA and Health Technology Assessment Council (HTAC) to determine minimum distribution standards. The enactment thereby vested substantial discretion in executive and administrative agencies in responding to the pandemic.
Executive Orders and FDA Emergency Use Authorization (EUA)
Executive Order No. 121 delegated authority to the FDA Director-General to issue Emergency Use Authorizations for COVID‑19 drugs and vaccines. E.O. 121 set conditions for EUA issuance: a reasonable belief in likely effectiveness based on totality of evidence (including adequate, well‑known controlled trials), a favorable benefit‑risk balance, and absence of adequate, approved, and available alternatives. The EUA process explicitly permits consideration of foreign clinical data, and an EUA precludes the need for completion of clinical trials in the Philippines before use. The Court noted that the FDA granted an EUA to Sinovac on February 22, 2021, considering clinical data and the EUAs of counterpart national regulatory authorities.
Procurement Law: R.A. No. 11525 and Negotiated Procurement
The Court observed that R.A. No. 11525 (COVID‑19 Vaccination Program Act of 2021) exempted procurement of COVID‑19 vaccines and ancillary supplies from the general public bidding requirement, authorizing negotiated procurement under emergency cases pursuant to Section 53(b) of R.A. No. 9184. The law authorized the DOH and the National Task Force (NTF) to negotiate and approve procurement terms, and permitted LGUs to enter into various supply arrangements following such negotiations. R.A. No. 11525 further permitted procurement only of vaccines that possess FDA registration or an EUA. Given the FDA’s EUA for Sinovac and the statutory allowance for negotiated procurement, the Court found no legal basis for mandating additional local clinical trials or public bidding as sought by petitioner.
Limits of Judicial Fact‑Finding and Appropriateness of Forum
The Court stressed that challenges to vaccine efficacy are factual questions requiring presentation and assessment of clinical trial data—matters beyond the Supreme Court’s role as a trier of facts. The doctrine of hierarchy of courts requires that petitions for manda
...continue readingCase Syllabus (UDK No. 16838)
Nature of the Case and Reliefs Sought
- Petition for writ of mandamus filed by Pedrito M. Nepomuceno (petitioner) against respondents President Rodrigo R. Duterte, Secretary Francisco Duque, the Department of Health (DOH), the Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID) and Gen. Carlito Galvez Jr. (Ret.), Chief Implementer of the National Task Force Against COVID-19 (respondents).
- Petitioner seeks to compel respondents to observe Food and Drug Administration (FDA) rules on acquisition, procurement and use of drugs, with particular focus on:
- Requiring trials and procurement procedures for COVID-19 vaccines (specifically Sinovac vaccines) to be observed in accordance with law and FDA rules;
- Directing the DOH FDA to issue a Cease-and-Desist Order for purchase and use of the Sinovac vaccine;
- Requiring that Sinovac and all other COVID-19 vaccines undergo required trials in the Philippines before emergency and/or regular use.
- Central factual concern expressed by petitioner: national government plan to procure Sinovac vaccine despite reports casting doubt on Sinovac’s efficacy and alleged absence of concrete Philippine-specific studies on its effectiveness against COVID-19 (SARS-CoV-2).
Preliminary Jurisdictional Determination — Dismissal of President Duterte as Respondent
- The Court held that President Rodrigo Duterte must be dropped as a respondent because a sitting President cannot be sued during tenure.
- Rationale: settled rule of presidential immunity from suit during the incumbent’s tenure, applied regardless of the nature of the suit.
- Authorities and precedents relied upon in this determination include:
- De Lima v. President Duterte (G.R. No. 227635, Oct. 15, 2019) — reaffirming presidential immunity applies regardless of the nature of the suit and that immunity need not be expressly provided in the Constitution.
- Historical record from the 1986 Constitutional Commission and jurisprudence construing immunity under the 1973 and 1987 Constitutions.
- Rubrico v. Macapagal-Arroyo and other precedents confirming preservation of the incumbent President’s immunity from suit.
- Soliven v. Makasiar and David v. Macapagal-Arroyo — explaining the rationale for immunity (to assure undistracted exercise of Presidential duties and to preserve dignity of the office).
- The Court emphasized that presidential immunity:
- Is not intended to shield the President from all accountability but to prevent distraction and harassment while in office; removal or accountability occurs only through constitutionally prescribed modes (e.g., impeachment).
- Does not require the President to personally invoke the privilege in each case; requiring such invocation would defeat the privilege’s purpose.
- Consequence: because the petition named the incumbent President, he is not a proper party and must be dropped.
Governing Legal Standard for Writ of Mandamus
- The petition was evaluated under Section 3, Rule 65 of the Revised Rules of Court (Petition for mandamus), which requires:
- A showing that a tribunal, corporation, board, officer or person unlawfully neglects the performance of an act which the law specifically enjoins as a duty resulting from office, trust or station; or unlawfully excludes another from use and enjoyment of a right or office to which such other is entitled;
- No other plain, speedy and adequate remedy in the ordinary course of law;
- Verified petition alleging facts with certainty and a sworn certification of non-forum shopping.
- The Court stated that a writ of mandamus may issue in two situations:
- To compel performance of a ministerial duty specifically enjoined by law; or
- To remedy unlawful exclusion from a right or office.
- Emphasis on ministerial duty requirement: mandamus cannot compel discretionary acts.
Ministerial vs. Discretionary Duties — Applicable Jurisprudence
- The Court applied established distinctions between ministerial and discretionary duties:
- A ministerial act is performed in a prescribed manner upon a given state of facts, obedience to a legal mandate, without the exercise of official discretion or judgment.
- A discretionary act involves judgment or choice as to how or when the duty shall be performed; mandamus does not compel discretionary acts.
- Authorities cited to explain and apply the distinction:
- Philippine Coconut Authority v. Primex Coco Products, Inc. — mandamus lies only to compel ministerial duties.
- Laygo, et al. v. Municipal Mayor of Solano, Nueva Vizcaya and Roble Arrastre, Inc. v. Villaflor — defining discretion and ministerial duties in public functionaries.
- For a writ of mandamus, petitioner must demonstrate:
- Clear legal right to the relief demanded; and
- An imperative duty on the respondent to perform the act required.
- The writ will not issue where issuance would be nugatory, unavailing, or useless.
Application of Mandamus Standard to the Petition — Failure to Allege a Ministerial Duty
- The Court found petitioner failed to point to any specific provision of law that enjoins respondents to conduct clinical trials or observe particular procurement mandates in the manner petitioner sought to compel.
- At the relevant time when the national government planned procurement and contracts for Sinovac:
- There was no law mandating the mandatory conduct of clinical trials for the procurement of any COVID-19 vaccine, including Sinovac.
- Section 12 of R.A. No. 11494 had suspended the requirement of Phase IV trials for COVID-19 medication and vaccines for a three-month period.
- The Court concluded the petition sought to compel what would be discretionary functions of the executive rather than ministerial acts.